Fakeeh Care Group announces final IPO price of $15.3 per share | Healthcare Asia Magazine
, Middle East
114 views
Photo from Lara Jameson on Pexels

Fakeeh Care Group announces final IPO price of $15.3 per share

Subscription period is on 21 and 22 May.

Saudi Arabia’s Fakeeh Care Group (FCG) has set a final offer price of $15.3 (SAR57.5) for its initial public offering (IPO).

The company’s announcement follows its completion of the institutional book-building process, drawing total orders of $90.9b (SAR341b).

ALSO READ: Abu Dhabi to launch new AI academy for health workforce boost

The final price values FCG at a market capitalisation of approximately $3.6b (SAR13.3b), with the offering raising gross proceeds of $773.3m (SAR 2.9b) for the company and the selling shareholders.

Moreover, the subscription period for individual investors will commence on 21 May until 22 May.

SAR1 = $0.27

 

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

Digital biomarkers market to soar to $43.3B by 2034
It will be driven by the rising prevalence of chronic diseases and advancements in digital health technologies. 
Healthcare
What fuels APAC’s healthcare logistics market?
One key driver is the rising demand for efficient supply chain management.
Healthcare
Australia invests $721m in upcoming Queensland Cancer Centre
The new facility is poised to offer treatments, such as proton beam therapy and nuclear theranostics.
Healthcare